InMed Pharmaceuticals Inc.
INM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INM
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing proprietary small-molecule product candidates for diseases with high unmet medical needs, with a focus on cannabinoid-based therapeutics.
Key risk: Financing uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$7.4M
Cash Runway
10.1 moLead Asset
inm-901 (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2029Financial data as of Mar 31, 2026.
Tracking 1 pipeline candidate · 1 clinical trial · 1 catalyst for InMed Pharmaceuticals Inc..
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing proprietary small-molecule product candidates for diseases with high unmet medical needs, with a focus on cannabinoid-based therapeutics.
- InMed is advancing proprietary small molecule product candidates through preclinical and clinical development for high unmet medical needs [sec_mda · as of 2025-09-23].
- The company reported cash and equivalents of $5.2M as of 2026-03-31 [sec].
- Net income was -$3.0M for the period ending 2026-03-31 [sec].
- Shareholders' equity stood at $13.4M as of 2026-03-31 [sec].
- InMed expects expenses to increase substantially as it continues R&D and clinical trials for its product candidates [sec_mda · as of 2026-05-06].
What works
- Experienced executive team and board with proven track records in pharmaceutical R&D, manufacturing, clinical trials, regulatory approvals, and commercialization [sec_mda · as of 2025-09-23].
- The company has a clear strategy to develop and produce proprietary small molecule candidates and advance them through preclinical and clinical proof-of-concept [sec_mda · as of 2025-09-23].
What to weigh
- InMed has a history of operating losses and expects to continue incurring substantial operating losses and negative cash flows for the foreseeable future [sec_mda · as of 2026-05-06].
- The company will need additional financing to complete development of its product candidates, and there is uncertainty about its ability to raise funds on acceptable terms [sec_mda · as of 2026-05-06].
- InMed cannot predict when, if ever, material net cash inflows will commence from its product candidates, even if approved [sec_mda · as of 2026-05-06].
From the filings
Quoted directly from source documents.
InMed's leadership team has extensive pharmaceutical experience.
“Experienced executive team and board of directors with proven track records.”
SEC MD&A · September 23, 2025
InMed expects expenses to increase substantially.
“We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we continue the research and development of and the clinical trials for our Product Candidates.”
SEC MD&A · May 6, 2026
InMed will need additional financing to complete development.
“will be necessary to complete the remainder of the development of our Product Candidates or to develop and commercialize additional Products.”
SEC MD&A · May 6, 2026
InMed cannot predict when material net cash inflows will start.
“We are also unable to predict when, if ever, material net cash inflows will commence from our Product Candidates, if approved.”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2029-12-31 · Phase2_Topline · mt-002 — Phase 2 Readout: mt-002 — Topline data from the Phase 2 trial of mt-002 will be a key milestone for InMed's pipeline.
Risks & what to watch (3)›
Key risks
- Financing uncertainty — InMed may not be able to raise additional funds on acceptable terms, which could delay or halt development [sec_mda · as of 2026-05-06].
- Operating losses continue — The company expects substantial operating losses and negative cash flows for the foreseeable future [sec_mda · as of 2026-05-06].
- No guaranteed revenue — InMed cannot predict when, if ever, material net cash inflows will commence from product candidates [sec_mda · as of 2026-05-06].
What to watch
- Upcoming Phase 2 readout for mt-002 expected by 2029-12-31 [catalyst].
- Ability to secure additional financing to fund ongoing R&D and clinical trials [sec_mda · as of 2026-05-06].
- Progress of preclinical and clinical development activities for product candidates [sec_mda · as of 2026-05-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run InMed Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available InMed Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.1 months
D/E 0.33 · 0% dilution
Lead: Preclinical
1 candidate
1 upcoming, next in ~1219d
34 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 2.9%
- Days to cover
- 0.6
- Shares short
- 95,636
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INM short interestGovernance
Frequently asked questions
What is the AI investment thesis for InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing proprietary small-molecule product candidates for diseases with high unmet medical needs, with a focus on cannabinoid-based therapeutics.
What is InMed Pharmaceuticals Inc.'s lead drug candidate?
InMed Pharmaceuticals Inc.'s most advanced tracked candidate is inm-901 (Preclinical) for Alzheimer's disease.
What is InMed Pharmaceuticals Inc.'s next catalyst?
InMed Pharmaceuticals Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: mt-002" — expected December 31, 2029.
Who is the CEO of InMed Pharmaceuticals Inc.?
Mr. Eric A. Adams B.S. Chem., M.I.B. is the chief executive officer of InMed Pharmaceuticals Inc. (INM).
Where is InMed Pharmaceuticals Inc. headquartered?
InMed Pharmaceuticals Inc. (INM) is headquartered in Vancouver, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.